» Articles » PMID: 20197687

Impact of Mycophenolate Mofetil on Wound Complications and Lymphoceles After Kidney Transplantation

Overview
Publisher Karger
Specialty Nephrology
Date 2010 Mar 4
PMID 20197687
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aims: Despite improved efficacy, modern immunosuppressive agents may show unanticipated side effects. In this study we investigated the possible interactions of mycophenolate mofetil (MMF) with wound healing and lymphocele formation.

Methods: We conducted a retrospective single-center analysis in 144 patients receiving a cyclosporine A-based immunosuppression with prednisolone and either MMF (n = 77) or azathioprine (AZA, n = 77). Endpoints were incidences of lymphocele formation and non-primary wound healing during 6 months' follow-up.

Results: AZA-treated patients had more rejection episodes and consecutively more steroid pulses, both being potential risk factors for endpoints. No graft was lost in any group and graft function was comparable. AZA patients demonstrated a trend for more frequent wound infections. Fluid accumulation around the graft, however, was more frequent in the MMF group (OR = 2.6; p = 0.03). Consequently, more drainage maneuvers (17 vs. 5 interventions) and sclerotherapies (8 vs. 0 interventions) were undertaken in MMF patients. Pre-assigned risk factors for lymphoceles reported before did not differ between both cohorts; patients experiencing acute rejection episodes had even less symptomatic lymphoceles (n = 23).

Conclusion: We found a possible relationship between the administration of MMF and lymphocele formation. To avoid the hazard of reinterventions, the prolongation of hospitalization and impairment of graft function, it requires awareness and attention in patients treated with this immunosuppressant.

Citing Articles

The effects of lymphocele formation after living donor kidney transplantation on mid-term allograft function.

Kuhn C, Janigen B, Matuschik L, Rieger M, Sidler D, Zschiedrich S BMC Nephrol. 2025; 26(1):59.

PMID: 39915729 PMC: 11804078. DOI: 10.1186/s12882-025-03989-5.


Outcomes of ABO-incompatible kidney transplants with very high isoagglutinin titers: a single-center experience and literature review.

Naciri Bennani H, Bobo Barry K, Noble J, Malvezzi P, Jouve T, Rostaing L Front Immunol. 2024; 15:1504495.

PMID: 39687613 PMC: 11647008. DOI: 10.3389/fimmu.2024.1504495.


Mammalian Target of Rapamycin Inhibitors and Wound Healing Complications in Kidney Transplantation: Old Myths and New Realities.

Khalil M, Al-Ghamdi S, Dawood U, Ahmed Khamis S, Ishida H, Chong V J Transplant. 2022; 2022:6255339.

PMID: 35265364 PMC: 8901320. DOI: 10.1155/2022/6255339.


ABO incompatibility in renal transplantation.

Mohamed M, Sweeney T, Alkhader D, Nassar M, Alqassieh A, Lakhdar S World J Transplant. 2021; 11(9):388-399.

PMID: 34631470 PMC: 8465511. DOI: 10.5500/wjt.v11.i9.388.


Effect of subcutaneous tissue depth on outcomes of kidney transplantation.

Ruiz R, Cox T, McKenna G, Onaca N, Testa G, Fernandez H Proc (Bayl Univ Med Cent). 2021; 34(2):237-241.

PMID: 33678955 PMC: 7901397. DOI: 10.1080/08998280.2020.1852835.